These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

264 related articles for article (PubMed ID: 24526661)

  • 1. Differential effects of fingolimod on B-cell populations in multiple sclerosis.
    Nakamura M; Matsuoka T; Chihara N; Miyake S; Sato W; Araki M; Okamoto T; Lin Y; Ogawa M; Murata M; Aranami T; Yamamura T
    Mult Scler; 2014 Sep; 20(10):1371-80. PubMed ID: 24526661
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Fingolimod therapy modulates circulating B cell composition, increases B regulatory subsets and production of IL-10 and TGFβ in patients with Multiple Sclerosis.
    Blumenfeld S; Staun-Ram E; Miller A
    J Autoimmun; 2016 Jun; 70():40-51. PubMed ID: 27055778
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Compositional changes of B and T cell subtypes during fingolimod treatment in multiple sclerosis patients: a 12-month follow-up study.
    Claes N; Dhaeze T; Fraussen J; Broux B; Van Wijmeersch B; Stinissen P; Hupperts R; Hellings N; Somers V
    PLoS One; 2014; 9(10):e111115. PubMed ID: 25360562
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Suppressed pro-inflammatory properties of circulating B cells in patients with multiple sclerosis treated with fingolimod, based on altered proportions of B-cell subpopulations.
    Miyazaki Y; Niino M; Fukazawa T; Takahashi E; Nonaka T; Amino I; Tashiro J; Minami N; Fujiki N; Doi S; Kikuchi S
    Clin Immunol; 2014 Apr; 151(2):127-35. PubMed ID: 24607506
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical immunology of the sphingosine 1-phosphate receptor modulator fingolimod (FTY720) in multiple sclerosis.
    Mehling M; Johnson TA; Antel J; Kappos L; Bar-Or A
    Neurology; 2011 Feb; 76(8 Suppl 3):S20-7. PubMed ID: 21339487
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Differential effects of disease modifying drugs on peripheral blood B cell subsets: A cross sectional study in multiple sclerosis patients treated with interferon-β, glatiramer acetate, dimethyl fumarate, fingolimod or natalizumab.
    Kemmerer CL; Pernpeintner V; Ruschil C; Abdelhak A; Scholl M; Ziemann U; Krumbholz M; Hemmer B; Kowarik MC
    PLoS One; 2020; 15(7):e0235449. PubMed ID: 32716916
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Sphingosine-1-phosphate signaling system and the innovative mechanism of action of fingolimod in treatment of multiple sclerosis: review of foreign literature].
    Shmyrev VI; Kryzhanovskiĭ SM; Danilycheva IV
    Zh Nevrol Psikhiatr Im S S Korsakova; 2012; 112(2 Pt 2):93-7. PubMed ID: 22677684
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Transcriptome profiling of peripheral blood immune cell populations in multiple sclerosis patients before and during treatment with a sphingosine-1-phosphate receptor modulator.
    Angerer IC; Hecker M; Koczan D; Roch L; Friess J; Rüge A; Fitzner B; Boxberger N; Schröder I; Flechtner K; Thiesen HJ; Winkelmann A; Meister S; Zettl UK
    CNS Neurosci Ther; 2018 Mar; 24(3):193-201. PubMed ID: 29314605
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Basic mechanisms of action of fingolimod in relation to multiple sclerosis].
    García-Merino JA; Sánchez AJ
    Rev Neurol; 2012 Jul; 55(1):31-7. PubMed ID: 22718407
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Fingolimod: direct CNS effects of sphingosine 1-phosphate (S1P) receptor modulation and implications in multiple sclerosis therapy.
    Groves A; Kihara Y; Chun J
    J Neurol Sci; 2013 May; 328(1-2):9-18. PubMed ID: 23518370
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Fingolimod for multiple sclerosis: mechanism of action, clinical outcomes, and future directions.
    Mehling M; Kappos L; Derfuss T
    Curr Neurol Neurosci Rep; 2011 Oct; 11(5):492-7. PubMed ID: 21789537
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The impact of fingolimod (FTY720) in neuroimmunologic diseases: mechanisms beyond immunomodulation.
    Haghikia A; Gold R
    Am J Pathol; 2010 Jun; 176(6):2599-601. PubMed ID: 20395429
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Th17 central memory T cells are reduced by FTY720 in patients with multiple sclerosis.
    Mehling M; Lindberg R; Raulf F; Kuhle J; Hess C; Kappos L; Brinkmann V
    Neurology; 2010 Aug; 75(5):403-10. PubMed ID: 20592255
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Fingolimod treatment in multiple sclerosis leads to increased macular volume.
    Nolan R; Gelfand JM; Green AJ
    Neurology; 2013 Jan; 80(2):139-44. PubMed ID: 23223539
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Fingolimod is a potential novel therapy for multiple sclerosis.
    Aktas O; Küry P; Kieseier B; Hartung HP
    Nat Rev Neurol; 2010 Jul; 6(7):373-82. PubMed ID: 20551946
    [TBL] [Abstract][Full Text] [Related]  

  • 16. T-cell response against varicella-zoster virus in fingolimod-treated MS patients.
    Ricklin ME; Lorscheider J; Waschbisch A; Paroz C; Mehta SK; Pierson DL; Kuhle J; Fischer-Barnicol B; Sprenger T; Lindberg RL; Kappos L; Derfuss T
    Neurology; 2013 Jul; 81(2):174-81. PubMed ID: 23700335
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Fingolimod treatment in multiple sclerosis].
    Tanaka M
    Nihon Rinsho; 2014 Nov; 72(11):2010-4. PubMed ID: 25518386
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Development of oral agent in the treatment of multiple sclerosis: how the first available oral therapy, fingolimod will change therapeutic paradigm approach.
    Gasperini C; Ruggieri S
    Drug Des Devel Ther; 2012; 6():175-86. PubMed ID: 22888218
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antigen-specific adaptive immune responses in fingolimod-treated multiple sclerosis patients.
    Mehling M; Hilbert P; Fritz S; Durovic B; Eichin D; Gasser O; Kuhle J; Klimkait T; Lindberg RL; Kappos L; Hess C
    Ann Neurol; 2011 Feb; 69(2):408-13. PubMed ID: 21387383
    [TBL] [Abstract][Full Text] [Related]  

  • 20. FTY720 and central memory: out of sight, out of mind.
    Slavin AJ; Zamvil SS
    Neurology; 2010 Aug; 75(5):388-9. PubMed ID: 20610831
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 14.